Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery (BC-PC)

Perioperative Use of a Beta-adrenergic Blocker and a COX-2 Inhibitor in Patients Undergoing Surgery With Primary Pancreatic Cancer: Intervention Aiming to Reduce Pro-metastatic Processes

In Israel, of the ~1000 patients diagnosed annually with pancreatic cancer (PC), approximately 250 (25 percent) will be eligible for curative surgery, of which 80 percent will succumb to post-surgical metastatic disease. A reduction in post-surgical metastatic disease will save dozens of patients in Israel annually, and tens-of thousands-around the world. The short perioperative period (days to weeks around surgery) is characterized by stress-inflammatory responses, including catecholamines (CAs, e.g., adrenaline) and prostaglandins (PGs, e.g., prostaglandin-E2) release, and induce deleterious pro-metastatic effects. Animal studies implicated excess perioperative release of CAs and PGs in facilitating cancer progression by affecting the malignant tissue, its local environment, and anti-metastatic immune functions. Congruently, our animal studies indicate that combined use of the beta-adrenergic blocker, propranolol, and the prostaglandins inhibitor, etodolac - but neither drug separately - efficiently prevented post-operative metastatic development. We recently conducted two clinical trials in three medical centers in Israel, recruiting breast (n=38) and colorectal (n=34) cancer patients, assessing the safety and short-term efficacy of perioperative propranolol and etodolac treatment. Drugs were well tolerated, without severe adverse events. Importantly, molecular/biological analyses of the excised primary tumor indicated that drug treatment caused promising anti-metastatic transformations, as well as improvements in immune and inflammatory indices. These included (i) decreased tumor cell capacity to migrate, (ii) reduced pro-metastatic capacity of the malignant tissue, and (iii) improvement in immune infiltrating into the tumor (Paper published in Clinical Cancer Research, 2017). Herein, we propose to conduct a double-blind placebo-controlled two-arm Phase II clinical trial in 210 pancreatic cancer patients undergoing curative surgery in Israel. A perioperative 35-day drug treatment will be initiated 5 days before surgery. Primary outcomes will include (i) 1-year disease-free-survival (DFS), and 5-year overall survival (OS); and (ii) biological markers in blood samples, and in the excised tumor tissue. Secondary outcomes will include safety indices and psychological measures of depression, anxiety, distress, and fatigue.

Study Overview

• Status: Recruiting
• Conditions: Pancreatic Neoplasms
• Intervention / Treatment: Other: Placebo; Drug: Propranolol and etodolac

• Study Type: Interventional
• Enrollment (Anticipated): 210
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Oded Zmora, MD; Phone Number: +97289779202; Email: ozmora@post.tau.ac.il

Study Locations

• Israel
  • Tel Hashomer, Israel, 45858
    • Recruiting
    • Sheba Medical Center
    • Contact: Talia Golan, MD; Email: Talia.Golan@sheba.health.gov.il
  • Tel-Aviv, Israel, 6423906
    • Not yet recruiting
    • Sourasky Medical Center
    • Contact: Ido Nachmany, MD
    • Contact: Email: idon@tlvmc.gov.il
  • Tsrifin, Israel, 70300
    • Recruiting
    • Asaf Harofeh Medical Center
    • Contact: Oded Zmora, MD; Phone Number: +97289779202; Email: ozmora@post.tau.ac.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Newly diagnosed Stage I or II adenocarcinoma of the head, neck, or uncinated- process of the pancreas.
• Surgically resectable disease (R0 or R1) by spiral CT chest and abdomen scan, No distant metastases
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
• Signed informed consent form
• Willing and able to comply with study procedures
• Men and women from age 20 up to age 80

Exclusion Criteria:

• Patients with metastatic disease, known prior to surgery
• Patients with history or concomitant malignant disease of any type (except for the current pancreatic cancer
• Patients who were treated with chemotherapy in the last 10 years for any reason
• Patients in whom surgical resection is planned without curative intent
• Patients exhibiting levels Carbohydrate antigen (CA) 19-9 above 500
• Patients with renal failure, measured by creatinine level >1.5
• Patients with significant heart failure (NYHA functional class 3 or higher),
• Patients with significant liver failure (known cirrhosis)
• Patients suffering from active asthma
• Patients with known allergy to any medication from the non-steroidal anti- inflammatory or beta-blockers drug group
• Patients treated chronically with any type of a beta-adrenergic blocker or a cyclooxygenase (COX) inhibitor
• Patients with bradycardia or second or third degree atrioventricular block (AV) block
• Patients with a history of cerebrovascular accident (CVA) or established diagnosed transient ischemic attack (TIA)
• Patients with prinzmetal's angina
• Patients with right sided heart failure owing to pulmonary hypertension
• Patients with significant diagnosed cardiomegaly
• Patients with (current) pheochromocytoma
• Patients with chronic Digoxin treatment
• Patients with active peptic disease
• Patients with peripheral vascular disease
• Pregnant woman
• Special population with impaired judgment
• Patients currently actively participating in any other clinical trial
• contraindication for Whipple procedure
• Patients suffering from sick sinus syndrome

• Patients with borderline resectable tumors, as defined by one of the following:

  • an infiltration >180° of the portal vein
  • abutment of the tumor to the superior mesenteric artery
  • infiltration of the superior mesenteric artery or the celiac trunk

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Same schedule as in the active comparator arm	Other: Placebo; Placebo
Active Comparator: Propranolol and etodolac; Both study medications will be given orally for an intervention phase of 35 days as follows. Etodolac:400mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery and the following morning, 40 mg PO bid for following 6.5 days, and 20 mg PO bid for next 22 days.	Drug: Propranolol and etodolac; A perioperative combined drug regimen; Other Names: Deralin and etopan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of cancer recurrence	Data regrading post-surgical recurrence will be recorded at 1,3,6,12,18,24,36,48, and 60 following surgery	From the date of surgery until malignant disease is identified, assessed up to 60 months post-surgery
Biomarkers in extracted tumor tissue samples	Epithelial-to-mesenchymal-transition ( EMT) status and natural-killer cell, macrophage, T-cell, and B-cell infiltration levels into tumor tissue (as assessed by messenger RNA profiling of tissue samples.	An average of one year following surgery
Biomarkers in blood samples	Cytokine levels in blood samples (interleukin-6, interleukin-10, C-reactive protein, interferon-gamma, and vascular endothelial growth factor and additional exploratory analysis of other cytokines)	An average of one year following surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with treatment related adverse events	According to the Clavien-Dindo classification system (7 grades of events depicting the severity of the event)	30 days following surgery
Depression, Anxiety, Global distress	Assessed by changes on the brief symptom inventory 18 questionnaire (this questionnaire assess all three scales for depression, anxiety and global distress)	At baseline and at 30 days post-surgery
Fatigue	4 items related to fatigue in the 36 item short-form survey questionnaire.	At baseline and at 30 days post-surgery

Collaborators and Investigators

• Sponsor: Assaf-Harofeh Medical Center
• Collaborators: Sheba Medical Center
• Investigators: Principal Investigator: Oded Zmora, MD, Asaf Harofeh Medical Center

Publications and helpful links

General Publications

• Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu S. Perioperative inhibition of beta-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain Behav Immun. 2018 Oct;73:294-309. doi: 10.1016/j.bbi.2018.05.014. Epub 2018 May 22.
• Shaashua L, Shabat-Simon M, Haldar R, Matzner P, Zmora O, Shabtai M, Sharon E, Allweis T, Barshack I, Hayman L, Arevalo J, Ma J, Horowitz M, Cole S, Ben-Eliyahu S. Perioperative COX-2 and beta-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. Clin Cancer Res. 2017 Aug 15;23(16):4651-4661. doi: 10.1158/1078-0432.CCR-17-0152. Epub 2017 May 10.

Study record dates

Study Major Dates

• Study Start (Anticipated): November 20, 2019
• Primary Completion (Anticipated): January 1, 2026
• Study Completion (Anticipated): January 1, 2026

Study Registration Dates

• First Submitted: January 23, 2019
• First Submitted That Met QC Criteria: February 11, 2019
• First Posted (Actual): February 12, 2019

Study Record Updates

• Last Update Posted (Actual): November 20, 2019
• Last Update Submitted That Met QC Criteria: November 19, 2019
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Keywords: COX-2 inhibitor; Propranolol; Beta-blocker; Etodolac
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Physiological Effects of Drugs; Adrenergic beta-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Antihypertensive Agents; Vasodilator Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Cyclooxygenase 2 Inhibitors; Propranolol; Etodolac
• Other Study ID Numbers: 0308-17-ASF; MOH_2018-03-12_002226 (Registry Identifier: The Israeli Ministry of Health)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No